Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows in line with its trailing trend

Q2 FY2026 selling, general & admin of $47.58M rose 15.0% year over year, ahead of the +13.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.

Context

  • Selling, general & admin amounted to 60.4% of revenue in FY2025, down 27.7 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $282.03M (+68.6%) for the fiscal year ending Dec 2026, a step up from the +6.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$47.58M+0.5% QoQ
Last fiscal yearDec 2025
$167.27M+6.2% YoY
LTMJun 2026
$180.38M+13.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.0%+58.7%+43.6 pp
1 year+6.2%+68.6%+62.4 pp
3-year CAGR-3.2%+36.4%+39.6 pp
5-year CAGR+28.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
167.27M USD
Year-over-year change
+6.2%
4-year CAGR
-0.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 selling, general & admin of $180.38M is the 6th highest of the 10 companies compared; the peer median is $196.16M.
  • Its year-over-year change of +13.3% is the 7th highest of 10, against a peer median of +32.1%.
  • Selling, general & admin amounts to 58.5% of revenue for ADPT, versus a peer median of 62.5%.
ADPT Competitors Peer median
Selling, General & Admin for ADPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$585.83M +60.2%+111.8%85.9%
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M +10.5%+25.2%26.3%
ZLABZai Lab LimitedLTM Jun 2026$281.09M -1.1%+2.3%62.5%
SRRKScholar Rock Holding CorporationLTM Sep 2026$198.39M +32.1%+60.5%34804.4%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$196.16M +10.4%+50.3%32.9%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$180.38M +13.3%-3.2%58.5%
BEAMBeam Therapeutics Inc.LTM Jun 2026$125.4M +14.0%+9.0%80.4%
IRONDisc Medicine, Inc.LTM Sep 2026$82.59M +51.8%+67.0%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$69.2M +144.0%+94.7%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$69.19M +65.4%+42.7%30.7%
Peer median (excluding ADPT) $196.16M+32.1%+50.3%62.5%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.